MedTrace Logo

Assessment of KAN-101 in Celiac Disease (ACeD)

NCT04248855 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-08-06

Study results available
· View outcomes & findings →

Summary

A safety study of KAN-101 in patients with celiac disease. The study has two parts:

1. Part A - first in human study in which patients receive a single dose of KAN-101
2. Part B - patients will receive three doses of either KAN-101 or placebo

Conditions

Interventions

DRUG

KAN-101

Intravenous (IV) infusion

DRUG

Placebo

Intravenous (IV) infusion

Sponsors & Collaborators

  • Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

    lead INDUSTRY

Principal Investigators

  • Study Director · Kanyos Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2021-10-08
Completion
2021-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04248855 on ClinicalTrials.gov